Literature DB >> 21930761

Palmitoylation state impacts induction of innate and acquired immunity by the Salmonella enterica serovar typhimurium msbB mutant.

Qingke Kong1, David A Six, Qing Liu, Lillian Gu, Kenneth L Roland, Christian R H Raetz, Roy Curtiss.   

Abstract

Lipopolysaccharide (LPS), composed of lipid A, core, and O-antigen, is a major virulence factor of Salmonella enterica serovar Typhimurium, with lipid A being a major stimulator to induce the proinflammatory response via the Toll-like receptor 4 (TLR4)-MD2-CD14 pathway. While Salmonella msbB mutants lacking the myristate chain in lipid A were investigated widely as an anticancer vaccine, inclusion of the msbB mutation in a Salmonella vaccine to deliver heterologous antigens has not yet been investigated. We introduced the msbB mutation alone or in combination with mutations in other lipid A acyl chain modification genes encoding PagL, PagP, and LpxR into wild-type S. enterica serovar Typhimurium. The msbB mutation reduced virulence, while the pagL, pagP, and lpxR mutations did not affect virulence in the msbB mutant background when administered orally to BALB/c mice. Also, all mutants exhibited sensitivity to polymyxin B but did not display sensitivity to deoxycholate. LPS derived from msbB mutants induced less inflammatory responses in human Mono Mac 6 and murine macrophage RAW264.7 cells in vitro. However, an msbB mutant did not decrease the induction of inflammatory responses in mice compared to the levels induced by the wild-type strain, whereas an msbB pagP mutant induced less inflammatory responses in vivo. The mutations were moved to an attenuated Salmonella vaccine strain to evaluate their effects on immunogenicity. Lipid A modification caused by the msbB mutation alone and in combination with pagL, pagP, and lpxR mutations led to higher IgA production in the vaginal tract but still retained the same IgG titer level in serum to PspA, a test antigen from Streptococcus pneumoniae, and to outer membrane proteins (OMPs) from Salmonella.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21930761      PMCID: PMC3232669          DOI: 10.1128/IAI.05524-11

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  61 in total

1.  Mutation of waaN reduces Salmonella enterica serovar Typhimurium-induced enteritis and net secretion of type III secretion system 1-dependent proteins.

Authors:  P R Watson; A Benmore; S A Khan; P W Jones; D J Maskell; T S Wallis
Journal:  Infect Immun       Date:  2000-06       Impact factor: 3.441

2.  Rapid isolation method for lipopolysaccharide and lipid A from gram-negative bacteria.

Authors:  E C Yi; M Hackett
Journal:  Analyst       Date:  2000-04       Impact factor: 4.616

3.  Salmonella synthesizing 1-dephosphorylated [corrected] lipopolysaccharide exhibits low endotoxic activity while retaining its immunogenicity.

Authors:  Qingke Kong; David A Six; Kenneth L Roland; Qing Liu; Lillian Gu; C Michael Reynolds; Xiaoyuan Wang; Christian R H Raetz; Roy Curtiss
Journal:  J Immunol       Date:  2011-06-01       Impact factor: 5.422

4.  Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically modified strain of Salmonella typhimurium.

Authors:  C Clairmont; K C Lee; J Pike; M Ittensohn; K B Low; J Pawelek; D Bermudes; S M Brecher; D Margitich; J Turnier; Z Li; X Luo; I King; L M Zheng
Journal:  J Infect Dis       Date:  2000-06-05       Impact factor: 5.226

5.  Regulated delayed expression of rfc enhances the immunogenicity and protective efficacy of a heterologous antigen delivered by live attenuated Salmonella enterica vaccines.

Authors:  Qingke Kong; Qing Liu; Angela M Jansen; Roy Curtiss
Journal:  Vaccine       Date:  2010-07-03       Impact factor: 3.641

6.  Cutting edge: repurification of lipopolysaccharide eliminates signaling through both human and murine toll-like receptor 2.

Authors:  M Hirschfeld; Y Ma; J H Weis; S N Vogel; J J Weis
Journal:  J Immunol       Date:  2000-07-15       Impact factor: 5.422

7.  Genetics of swarming motility in Salmonella enterica serovar typhimurium: critical role for lipopolysaccharide.

Authors:  A Toguchi; M Siano; M Burkart; R M Harshey
Journal:  J Bacteriol       Date:  2000-11       Impact factor: 3.490

8.  Transfer of palmitate from phospholipids to lipid A in outer membranes of gram-negative bacteria.

Authors:  R E Bishop; H S Gibbons; T Guina; M S Trent; S I Miller; C R Raetz
Journal:  EMBO J       Date:  2000-10-02       Impact factor: 11.598

9.  Genetic and functional analysis of a PmrA-PmrB-regulated locus necessary for lipopolysaccharide modification, antimicrobial peptide resistance, and oral virulence of Salmonella enterica serovar typhimurium.

Authors:  J S Gunn; S S Ryan; J C Van Velkinburgh; R K Ernst; S I Miller
Journal:  Infect Immun       Date:  2000-11       Impact factor: 3.441

10.  Effect of antibiotic class and concentration on the release of lipopolysaccharide from Escherichia coli.

Authors:  M E Evans; M Pollack
Journal:  J Infect Dis       Date:  1993-06       Impact factor: 5.226

View more
  17 in total

Review 1.  New technologies in developing recombinant attenuated Salmonella vaccine vectors.

Authors:  Shifeng Wang; Qingke Kong; Roy Curtiss
Journal:  Microb Pathog       Date:  2012-11-08       Impact factor: 3.738

2.  Phosphate groups of lipid A are essential for Salmonella enterica serovar Typhimurium virulence and affect innate and adaptive immunity.

Authors:  Qingke Kong; David A Six; Qing Liu; Lillian Gu; Shifeng Wang; Praveen Alamuri; Christian R H Raetz; Roy Curtiss
Journal:  Infect Immun       Date:  2012-07-02       Impact factor: 3.441

3.  A divergent Pseudomonas aeruginosa palmitoyltransferase essential for cystic fibrosis-specific lipid A.

Authors:  Iyarit Thaipisuttikul; Lauren E Hittle; Ramesh Chandra; Daniel Zangari; Charneal L Dixon; Teresa A Garrett; David A Rasko; Nandini Dasgupta; Samuel M Moskowitz; Lars Malmström; David R Goodlett; Samuel I Miller; Russell E Bishop; Robert K Ernst
Journal:  Mol Microbiol       Date:  2013-11-27       Impact factor: 3.501

4.  Outer membrane vesicles derived from Salmonella Typhimurium mutants with truncated LPS induce cross-protective immune responses against infection of Salmonella enterica serovars in the mouse model.

Authors:  Qiong Liu; Qing Liu; Jie Yi; Kang Liang; Tian Liu; Kenneth L Roland; Yanlong Jiang; Qingke Kong
Journal:  Int J Med Microbiol       Date:  2016-08-25       Impact factor: 3.473

Review 5.  Pushing the envelope: LPS modifications and their consequences.

Authors:  Brent W Simpson; M Stephen Trent
Journal:  Nat Rev Microbiol       Date:  2019-07       Impact factor: 60.633

6.  Oral Salmonella msbB Mutant as a Carrier for a Salmonella-Based Vaccine for Prevention and Reversal of Type 1 Diabetes.

Authors:  Jacob Cobb; Jeffrey Rawson; Nelson Gonzalez; Michael Hensel; Fouad Kandeel; Mohamed I Husseiny
Journal:  Front Immunol       Date:  2021-05-24       Impact factor: 7.561

7.  Construction of Escherichia coli Mutant with Decreased Endotoxic Activity by Modifying Lipid A Structure.

Authors:  Qiong Liu; Yanyan Li; Xinxin Zhao; Xue Yang; Qing Liu; Qingke Kong
Journal:  Mar Drugs       Date:  2015-05-27       Impact factor: 5.118

8.  Salmonella enterica serovar Typhimurium ΔmsbB triggers exacerbated inflammation in Nod2 deficient mice.

Authors:  Anne-Kathrin Claes; Natalie Steck; Dorothee Schultz; Ulrich Zähringer; Simone Lipinski; Philip Rosenstiel; Kaoru Geddes; Dana J Philpott; Holger Heine; Guntram A Grassl
Journal:  PLoS One       Date:  2014-11-25       Impact factor: 3.240

9.  Toll-Like Receptor Activation by Generalized Modules for Membrane Antigens from Lipid A Mutants of Salmonella enterica Serovars Typhimurium and Enteritidis.

Authors:  Omar Rossi; Mariaelena Caboni; Aurel Negrea; Francesca Necchi; Renzo Alfini; Francesca Micoli; Allan Saul; Calman A MacLennan; Simona Rondini; Christiane Gerke
Journal:  Clin Vaccine Immunol       Date:  2016-04-04

10.  Development of Streptococcus pneumoniae Vaccines Using Live Vectors.

Authors:  Shifeng Wang; Roy Curtiss
Journal:  Vaccines (Basel)       Date:  2014-01-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.